Working... Menu
Trial record 32 of 239 for:    (armodafinil)

Modafinil vs Placebo for the Treatment of Methamphetamine Dependence (Modafinil)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00469508
Recruitment Status : Completed
First Posted : May 4, 2007
Results First Posted : March 15, 2013
Last Update Posted : March 15, 2013
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Steve Shoptaw, University of California, Los Angeles

Brief Summary:
Modafinil is a non-amphetamine type stimulant that acts as a wakefulness-promoting drug, and is approved for managing symptoms of narcolepsy (i.e., daytime somnolence). Its precise mechanism of action in promoting wakefulness remains unclear. This trial is a placebo-controlled double-blind trial of modafinil, on a platform of contingency management (CM) and individual cognitive-behavioral (CBT) counseling, for the treatment of methamphetamine dependence. Participants in this study will complete a 2-week baseline screening period during which they will provide urine samples and complete physical and psychological assessments to establish their eligibility for the study. In addition, participants will be asked to provide a blood or saliva specimen for genetic testing in order to identify genetic variations that influence response to methamphetamine and to treatment with modafinil. Upon successful completion of screening, participants will be randomly assigned to receive either modafinil (400mg qd) or placebo during the 12 weeks of the study. Neither the participants nor study staff will know who is receiving active medication or placebo. Regardless of medication condition, all participants will receive CM and weekly individual CBT counseling sessions to help them stop using methamphetamine and prevent relapse. They will attend the clinical research site (either at the UCLA Hollywood Clinic, or the Rancho Cucamonga site) three times per week, providing urine samples at each visit, completing data measures, and receiving individual CBT counseling on one visit each week. At the end of the 12-week study, the medication or placebo will be discontinued. Participants will return to the research site approximately 30 days following medication discontinuation for a brief health check to assess any possible lingering side effects and complete brief data measures.

Condition or disease Intervention/treatment Phase
Methamphetamine Dependence Drug: Modafinil Drug: Placebo Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Study Start Date : April 2007
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine

Arm Intervention/treatment
Active Comparator: Modafinil
Modafinil 400mg oral dose taken daily for 12 weeks
Drug: Modafinil
400mg pills taken orally daily for 12 wks.
Other Name: Provigil

Placebo Comparator: Placebo
Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
Drug: Placebo
400mg pills taken orally daily for 12 wks
Other Name: Sugar pill

Primary Outcome Measures :
  1. Clean Urine Drug Screen [ Time Frame: From randomization to end of week 12 ]
    Urine samples, collected thrice weekly, were tested for metabolites of MA using radioimmunoassay. Each subject had a possible of 36 urine drug screens to provide during the 12 weeks of medication. An aggregate measure of urine drug screen results was calculated - the Treatment Effectiveness Score (TES) - which is the average of the sum of MA-free urine specimens provided during the treatment period by participants in each treatment condition.

Secondary Outcome Measures :
  1. Retention [ Time Frame: 12 weeks ]
    The number of persons who completed the medication phase of the trial (12 weeks of medication).

Other Outcome Measures:
  1. VAS Score [ Time Frame: baseline and last observation during the 12 week treatment period ]
    To measure methamphetamine craving, mean change in craving based on visual analog scale (VAS) from 0 (not at all) to 100 (extremely) from baseline to the last week of observation during the 12 week treatment period. The last observation was carried forward if not available during week 12.

  2. BDI Score [ Time Frame: From baseline to end of treatment period (week 12). ]
    Self-reported depression: mean change on Beck Depression Index (BDI-II) assessed weekly during the 12 week medication phase. If the week12 measure was not available, the last observation was carried forward. 0 indicates no depression, 63 is the maximum indicating severe depression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. 18 years of age or older;
  2. meet DSM-IV criteria for methamphetamine dependence;
  3. willing and able to comply with study procedures;
  4. willing and able to provide written informed consent;
  5. if female, not pregnant or lactating and willing to use an acceptable method of barrier birth control (e.g. condoms) during the trial and for one month after discontinuation of study medication (modafinil may reduce the effectiveness of steroidal contraceptives both during administration and for one month after discontinuation).

Exclusion Criteria:

  1. have a medical condition that, in the study physician's judgment, may interfere with safe study participation (e.g., active TB, unstable cardiac, renal, or liver disease, unstable diabetes, or elevated liver enzymes (SGOT or SGPT) greater than 4 times the upper limit of normal);
  2. have a current neurological disorder (e.g., organic brain disease, dementia) or major psychiatric disorder not due to substance abuse (e.g., schizophrenia or bipolar illness) as assessed by the SCID and a medical history which would make study agent compliance difficult or which would compromise informed consent, or recent (past 30 days) history of suicide attempts and/or current serious suicidal intention or plan as assessed by the SCID and the BDI-II;
  3. currently on prescription medication that is known to interact with the study drug;
  4. have current dependence on cocaine, opiates, alcohol, or benzodiazepines, as defined by DSM-IV-TR criteria;
  5. have a history of alcohol dependence within the past three years;
  6. have a history of mitral valve prolapse, left ventricular hypertrophy, cardiac arrhythmias, angina, myocardial infarction, acute coronary syndrome (unstable angina), cardiac syncope or presyncope, or any EKG abnormalities that suggests the presence of one of these conditions;
  7. have a systolic blood pressure greater than 160, a diastolic blood pressure greater than 100 (i.e. cutoffs for stage 2 hypertension), and a heart rate greater than 70% of the maximum heart rate expected for their age (0.70(220-age)) at any of the study visits.
  8. any other circumstances that, in the opinion of the investigators, would compromise participant safety;
  9. have a history of sensitivity to modafinil.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00469508

Layout table for location information
United States, California
UCLA Vine Street Clinic
Hollywood, California, United States, 90038
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Steve Shoptaw, Ph.D. University of California, Los Angeles

Publications of Results:
Layout table for additonal information
Responsible Party: Steve Shoptaw, Professor, University of California, Los Angeles Identifier: NCT00469508     History of Changes
Obsolete Identifiers: NCT00462293
Other Study ID Numbers: P50DA018185-03 ( U.S. NIH Grant/Contract )
P50DA018185 ( U.S. NIH Grant/Contract )
First Posted: May 4, 2007    Key Record Dates
Results First Posted: March 15, 2013
Last Update Posted: March 15, 2013
Last Verified: February 2013

Keywords provided by Steve Shoptaw, University of California, Los Angeles:
Contingency Management
Crystal meth
Los Angeles

Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Stimulants
Physiological Effects of Drugs
Wakefulness-Promoting Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors